Radiotherapy & Oncology
Volume 97, Issue 2 , Pages 205-211 , November 2010

The use of PET in assessing tumor response after neoadjuvant chemoradiation for rectal cancer

  • Daisy Mak

      Affiliations

    • Radiation Oncology Centre, Austin Health, Heidelberg West, Australia
    • ,
  • Daryl Lim Joon

      Affiliations

    • Radiation Oncology Centre, Austin Health, Heidelberg West, Australia
    • ,
  • Michael Chao

      Affiliations

    • Radiation Oncology Victoria, East Melbourne, Australia
    • ,
  • Morikatsu Wada

      Affiliations

    • Radiation Oncology Centre, Austin Health, Heidelberg West, Australia
    • ,
  • Michael Lim Joon

      Affiliations

    • Radiation Oncology Centre, Austin Health, Heidelberg West, Australia
    • ,
  • Andrew See

      Affiliations

    • Radiation Oncology Centre, Austin Health, Heidelberg West, Australia
    • ,
  • Malcolm Feigen

      Affiliations

    • Radiation Oncology Centre, Austin Health, Heidelberg West, Australia
    • ,
  • Patricia Jenkins

      Affiliations

    • Radiation Oncology Centre, Austin Health, Heidelberg West, Australia
    • ,
  • Angelina Mercuri

      Affiliations

    • Radiation Oncology Centre, Austin Health, Heidelberg West, Australia
    • ,
  • Joanne McNamara

      Affiliations

    • Radiation Oncology Centre, Austin Health, Heidelberg West, Australia
    • ,
  • Aurora Poon

      Affiliations

    • PET Centre, Austin Health, Heidelberg West, Australia
    • ,
  • Vincent Khoo

      Affiliations

    • Radiation Oncology Centre, Austin Health, Heidelberg West, Australia
    • Department of Clinical Oncology, Royal Marsden Hospital NHS Foundation Trust, London, UK
    • Corresponding Author InformationCorresponding author. Address: Royal Marsden Hospital NHS Foundation Trust and the Institute of Cancer Research, London SW3 6JJ, United Kingdom.

Received 28 April 2009 ,Revised 24 May 2010 ,Accepted 31 May 2010.

References 

  1. Colorectal Cancer Collaborative Group. Adjuvant radiotherapy for rectal cancer: a systematic overview of 8507 patients from 22 randomised trials. Lancet 2001;358:1291–304.
  2. Swedish Rectal Cancer Trial. Improved survival with preoperative radiotherapy in resectable rectal cancer. N Engl J Med 1997;336:980–7.
  3. Sauer R, Becker H, Hohenberger W, et al. Preoperative versus postoperative chemoradiotherapy for rectal cancer. N Engl J Med. 2004;351:1731–1740
  4. Janjan NA, Abbruzzese J, Pazdur R, et al. Prognostic implications of response to preoperative infusional chemoradiation in locally advanced rectal cancer. Radiother Oncol. 1999;51:153–160
  5. Janjan NA, Khoo VS, Abbruzzese J, et al. Tumor downstaging and sphincter preservation with preoperative chemoradiation in locally advanced rectal cancer: the M.D. Anderson Cancer Center experience. Int J Radiat Oncol Biol Phys. 1999;44:1027–1038
  6. Valentini V, Aristei C, Glimelius B, et al. Multidisciplinary Rectal Cancer Management: 2nd European Rectal Cancer Consensus Conference (EURECA-CC2). Radiother Oncol. 2009;92:148–163
  7. Garcia-Aguilar J, Hernandez de Anda E, Sirivongs P, Lee SH, Madoff RD, Rothenberger DA. A pathologic complete response to preoperative chemoradiation is associated with lower local recurrence and improved survival in rectal cancer patients treated by mesorectal excision. Dis Colon Rectum. 2003;46:298–304
  8. Habr-Gama A, Perez RO, Nadalin W, et al. Operative versus nonoperative treatment for stage 0 distal rectal cancer following chemoradiation therapy: long-term results. Ann Surg. 2004;240:711–717discussion 717–18
  9. Chen CC, Lee RC, Lin JK, Wang LW, Yang SH. How accurate is magnetic resonance imaging in restaging rectal cancer in patients receiving preoperative combined chemoradiotherapy?. Dis Colon Rectum. 2005;48:722–728
  10. Denecke T, Rau B, Hoffmann KT, et al. Comparison of CT, MRI and FDG-PET in response prediction of patients with locally advanced rectal cancer after multimodal preoperative therapy: is there a benefit in using functional imaging?. Eur Radiol. 2005;15:1658–1666
  11. Kubota K. From tumor biology to clinical PET: a review of positron emission tomography (PET) in oncology. Ann Nucl Med. 2001;15:471–486
  12. Valentini V, Coco C, Cellini N, et al. Ten years of preoperative chemoradiation for extraperitoneal T3 rectal cancer: acute toxicity, tumor response, and sphincter preservation in three consecutive studies. Int J Radiat Oncol Biol Phys. 2001;51:371–383
  13. Gerard JP, Chapet O, Nemoz C, et al. Preoperative concurrent chemoradiotherapy in locally advanced rectal cancer with high-dose radiation and oxaliplatin-containing regimen: the Lyon R0-04 phase II trial. J Clin Oncol. 2003;21:1119–1124
  14. Nahas CS, Akhurst T, Yeung H, et al. Positron emission tomography detection of distant metastatic or synchronous disease in patients with locally advanced rectal cancer receiving preoperative chemoradiation. Ann Surg Oncol. 2008;15:704–711
  15. Davey K, Heriot AG, Mackay J, et al. The impact of 18-fluorodeoxyglucose positron emission tomography-computed tomography on the staging and management of primary rectal cancer. Dis Colon Rectum. 2008;51:997–1003
  16. Bassi MC, Turri L, Sacchetti G, et al. FDG-PET/CT imaging for staging and target volume delineation in preoperative conformal radiotherapy of rectal cancer. Int J Radiat Oncol Biol Phys. 2008;70:1423–1426
  17. Furukawa H, Ikuma H, Seki A, et al. Positron emission tomography scanning is not superior to whole body multidetector helical computed tomography in the preoperative staging of colorectal cancer. Gut. 2006;55:1007–1011
  18. Llamas-Elvira JM, Rodriguez-Fernandez A, Gutierrez-Sainz J, et al. Fluorine-18 fluorodeoxyglucose PET in the preoperative staging of colorectal cancer. Eur J Nucl Med Mol Imaging. 2007;34:859–867
  19. Tateishi U, Maeda T, Morimoto T, Miyake M, Arai Y, Kim EE, et al. Non-enhanced CT versus contrast-enhanced CT in integrated PET/CT studies for nodal staging of rectal cancer. Eur J Nucl Med Mol Imaging. 2007;34:1627–1634
  20. Valentini V, Coco C, Picciocchi A, et al. Does downstaging predict improved outcome after preoperative chemoradiation for extraperitoneal locally advanced rectal cancer? A long-term analysis of 165 patients. Int J Radiat Oncol Biol Phys. 2002;53:664–674
  21. Habr-Gama A, Perez RO, Proscurshim I, et al. Patterns of failure and survival for nonoperative treatment of stage c0 distal rectal cancer following neoadjuvant chemoradiation therapy. J Gastrointest Surg. 2006;10:1319–1328discussion 1328–19
  22. Guillem JG, Puig-La Calle J, Akhurst T, et al. Prospective assessment of primary rectal cancer response to preoperative radiation and chemotherapy using 18-fluorodeoxyglucose positron emission tomography. Dis Colon Rectum. 2000;43:18–24
  23. Kristiansen C, Loft A, Berthelsen AK, et al. PET/CT and histopathologic response to preoperative chemoradiation therapy in locally advanced rectal cancer. Dis Colon Rectum. 2008;51:21–25
  24. Capirci C, Rubello D, Chierichetti F, et al. Long-term prognostic value of 18F-FDG PET in patients with locally advanced rectal cancer previously treated with neoadjuvant radiochemotherapy. AJR Am J Roentgenol. 2006;187:W202–W208
  25. Kalff V, Duong C, Drummond EG, Matthews JP, Hicks RJ. Findings on 18F-FDG PET scans after neoadjuvant chemoradiation provides prognostic stratification in patients with locally advanced rectal carcinoma subsequently treated by radical surgery. J Nucl Med. 2006;47:14–22
  26. Capirci C, Rampin L, Erba PA, et al. Sequential FDG-PET/CT reliably predicts response of locally advanced rectal cancer to neo-adjuvant chemo-radiation therapy. Eur J Nucl Med Mol Imaging. 2007;34:1583–1593
  27. Schiepers C, Haustermans K, Geboes K, Filez L, Bormans G, Penninckx F. The effect of preoperative radiation therapy on glucose utilization and cell kinetics in patients with primary rectal carcinoma. Cancer. 1999;85:803–811
  28. Haberkorn U, Strauss LG, Dimitrakopoulou A, et al. PET studies of fluorodeoxyglucose metabolism in patients with recurrent colorectal tumors receiving radiotherapy. J Nucl Med. 1991;32:1485–1490
  29. van Waarde A, Cobben DC, Suurmeijer AJ, et al. Selectivity of 18F-FLT and 18F-FDG for differentiating tumor from inflammation in a rodent model. J Nucl Med. 2004;45:695–700
  30. Wieder HA, Geinitz H, Rosenberg R, et al. PET imaging with [18F]3′-deoxy-3′-fluorothymidine for prediction of response to neoadjuvant treatment in patients with rectal cancer. Eur J Nucl Med Mol Imaging. 2007;34:878–883
  31. Cascini GL, Avallone A, Delrio P, et al. 18F-FDG PET is an early predictor of pathologic tumor response to preoperative radiochemotherapy in locally advanced rectal cancer. J Nucl Med. 2006;47:1241–1248
  32. Wieder HA, Brucher BL, Zimmermann F, et al. Time course of tumor metabolic activity during chemoradiotherapy of esophageal squamous cell carcinoma and response to treatment. J Clin Oncol. 2004;22:900–908

PII: S0167-8140(10)00334-8

doi: 10.1016/j.radonc.2010.05.016

Radiotherapy & Oncology
Volume 97, Issue 2 , Pages 205-211 , November 2010

Article Tools

* Image Usage & Resolution